Last reviewed · How we verify
Epinephrine concentration of 1:1000000
Epinephrine concentration of 1:1000000 is a Sympathomimetic amine / Adrenergic agonist Small molecule drug developed by Al-Azhar University. It is currently in Phase 3 development for Anaphylaxis (emergency treatment), Cardiac arrest (ACLS protocol), Severe hypotension.
Epinephrine is an alpha and beta-adrenergic agonist that stimulates sympathetic nervous system receptors to increase heart rate, blood pressure, and bronchial airway diameter.
Epinephrine is an alpha and beta-adrenergic agonist that stimulates sympathetic nervous system receptors to increase heart rate, blood pressure, and bronchial airway diameter. Used for Anaphylaxis (emergency treatment), Cardiac arrest (ACLS protocol), Severe hypotension.
At a glance
| Generic name | Epinephrine concentration of 1:1000000 |
|---|---|
| Sponsor | Al-Azhar University |
| Drug class | Sympathomimetic amine / Adrenergic agonist |
| Target | Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Emergency Medicine / Cardiovascular / Anesthesia |
| Phase | Phase 3 |
Mechanism of action
Epinephrine binds to alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors throughout the body. This activation increases cardiac contractility and heart rate (beta-1), causes vasoconstriction (alpha-1), and promotes bronchodilation (beta-2). The 1:1000000 concentration indicates an extremely dilute formulation, typically used for local anesthetic adjuvants or specific clinical applications requiring minimal systemic exposure.
Approved indications
- Anaphylaxis (emergency treatment)
- Cardiac arrest (ACLS protocol)
- Severe hypotension
- Adjuvant to local anesthetics (vasoconstrictor at 1:1000000 dilution)
Common side effects
- Tachycardia
- Hypertension
- Tremor
- Anxiety
- Headache
- Palpitations
- Arrhythmias
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Epinephrine concentration of 1:1000000 CI brief — competitive landscape report
- Epinephrine concentration of 1:1000000 updates RSS · CI watch RSS
- Al-Azhar University portfolio CI
Frequently asked questions about Epinephrine concentration of 1:1000000
What is Epinephrine concentration of 1:1000000?
How does Epinephrine concentration of 1:1000000 work?
What is Epinephrine concentration of 1:1000000 used for?
Who makes Epinephrine concentration of 1:1000000?
What drug class is Epinephrine concentration of 1:1000000 in?
What development phase is Epinephrine concentration of 1:1000000 in?
What are the side effects of Epinephrine concentration of 1:1000000?
What does Epinephrine concentration of 1:1000000 target?
Related
- Drug class: All Sympathomimetic amine / Adrenergic agonist drugs
- Target: All drugs targeting Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors
- Manufacturer: Al-Azhar University — full pipeline
- Therapeutic area: All drugs in Emergency Medicine / Cardiovascular / Anesthesia
- Indication: Drugs for Anaphylaxis (emergency treatment)
- Indication: Drugs for Cardiac arrest (ACLS protocol)
- Indication: Drugs for Severe hypotension
- Compare: Epinephrine concentration of 1:1000000 vs similar drugs
- Pricing: Epinephrine concentration of 1:1000000 cost, discount & access